TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00432263
Drug: Genotropin (PN-180,307) Somatropin
Normalized name: somatropin Cartridge [Genotropin]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03224299
Drug: OCT - clear
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
Study: NCT03224299
Drug: OCT- tinted
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
Study: NCT03702400
Drug: Norepinephrine 5 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
Study: NCT01036113
Drug: EZN-2208
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
Study: NCT03009474
Drug: CJ-30060
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
Study: NCT03009474
Drug: Exforge tab 5/160mg, Crestor tab 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
Study: NCT03101254
Drug: LY3022855
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
Study: NCT01299753
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identically packed placebo
Study: NCT02712411
Drug: HCP1303
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712411
Drug: HGP1201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712411
Drug: HIP1402
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04157257
Drug: TDF tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF tablet 300mg QD
Study: NCT04157257
Drug: QL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL-007 tablets 200mg BID
Study: NCT03331900
Drug: COR388
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral capsule
Study: NCT03331900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral capsule
Study: NCT00952029
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00952029
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02076919
Drug: LHA510 Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
Study: NCT02076919
Drug: LHA510 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used for masking purposes
Study: NCT00952029
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03415282
Drug: RVT-501 0.5% topical ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
Study: NCT04409210
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
Study: NCT00626418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT00606177
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 0mg(4tablets)/day
Study: NCT05872698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01225939
Drug: AZD8329
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01225939
Drug: AZD8329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution
Study: NCT01940848
Drug: STW5 (Iberogast, BAY98-7411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied orally over 28 days, 20 drops STW 5 three times daily
Study: NCT01940848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied orally over 28 days, 20 drops placebo three times daily
Study: NCT02807922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00817635
Drug: LCI699
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 oral capsules
Study: NCT00817635
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone oral capsules
Study: NCT00817635
Drug: LCI699-matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699-matching placebo oral capsules
Study: NCT00817635
Drug: Eplerenone-matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone-matching placebo oral capsules
Study: NCT00633893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, twice daily, 12 months
Study: NCT02333643
Drug: CLS003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00878618
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
Study: NCT00878618
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
Study: NCT02864095
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02616861
Drug: IW-1973
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-1973 Tablet
Study: NCT02616861
Drug: Matching Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT02624219
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT02624219
Drug: MF59 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Study: NCT00649935
Drug: Azithromycin Tablets 600 mg
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, single dose fed
Study: NCT00649935
Drug: Zithromax® Tablets 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, single dose fed
Study: NCT02131324
Drug: DFD06 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04538755
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before sleep
Study: NCT01799161
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg capsule daily of Theophylline during 1st course, then adjusted dose
Study: NCT01623336
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
Study: NCT01623336
Drug: BIP 48 (Peginterferon alfa 2b 48kDA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
Study: NCT01771666
Drug: 99technetium-sulfur colloid radiolabel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04520178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02741310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT02167516
Drug: glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
Study: NCT02167516
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
Study: NCT04889690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02281318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9% sodium chloride solution
Study: NCT02281318
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
Study: NCT00601848
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03493269
Drug: BAY1834845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered.
Study: NCT02823548
Drug: Droglican
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
Study: NCT00851240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00003728
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003728
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003728
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003728
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003728
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003728
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446223
Drug: Inggenol Mebutate 0.015%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03182959
Drug: Avmacol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avmacol® tablets
Study: NCT00307905
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: homeopathic remedy
Study: NCT00307905
Drug: Placebo remedy
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical size, shape and taste of treatment medication
Study: NCT02506192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets (2x5mg) daily for 8 weeks
Study: NCT00650364
Drug: ProAmatine® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, single dose fasting
Study: NCT00872781
Drug: fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets
Normalized name: Quinapril and Hydrochlorothiazide Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432458
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
Study: NCT00216086
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid
Study: NCT02682446
Drug: H pylori eradication
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
Study: NCT02068625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with placebo for 7 days
Study: NCT01435213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo (capsules) administered orally
Study: NCT00038142
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
Study: NCT01230619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
Study: NCT00130741
Drug: CHT - herbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02490176
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were taken daily for 7 days
Study: NCT03336450
Drug: SHP615
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Study: NCT03336450
Drug: MHOS/SHP615
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHOS/SHP615
Study: NCT04761237
Drug: Goal-directed fluid therapy (GDET)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
Study: NCT00038142
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
Study: NCT01955694
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
Study: NCT01955694
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
Study: NCT01955694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02934035
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01450124
Drug: Boswellic acids (BOSWELAN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
Study: NCT01222936
Drug: LBH581
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
Study: NCT01327677
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25-50 mcg every 20 minutes
Study: NCT01327677
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mcg/demand dose with an 8 minute lock out
Study: NCT01370694
Drug: MK-8808
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03257124
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 160mg per oral daily (1 cycle of 28 days)
Study: NCT01370694
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01370694
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02909049
Drug: MEPIVACAÍNE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
Study: NCT00877734
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered tid for 11 weeks
Study: NCT03353480
Drug: Azithromycin Tablet manufactured in China
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Azithromycin Tablet manufactured in China
Study: NCT03353480
Drug: Azithromycin Tablet manufactured in US
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Azithromycin Tablet manufactured in US
Study: NCT03836768
Drug: DTRMWXHS-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTRMWXHS-12 capsules: 150 mg, 300 mg
Study: NCT04004910
Drug: Chemotherapy Drugs, Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
Study: NCT01880658
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
Study: NCT03107286
Drug: Tc-99M-MAG3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
Study: NCT00732472
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day repeat dose
Study: NCT04526912
Drug: VIB7734
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose
Study: NCT04526912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single dose matched to VIB7734.
Study: NCT03993119
Drug: Non-vitamin K antagonist oral anticoagulant
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulant
Study: NCT01085162
Drug: BMS747158
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
Study: NCT03683628
Drug: No PB-MNC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
Study: NCT01193153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: monthly by i.m. injection for 15 months
Study: NCT03777761
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for tucatinib
Study: NCT00172211
Drug: Physioneal
Normalized name: Physioneal 40 with 1.36% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01314001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch
Study: NCT00004936
Drug: iodinated contrast dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02748772
Drug: Pure chemotherapy（Xelox）
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
Study: NCT02340949
Drug: 5-Fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
Study: NCT02340949
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study: NCT00106314
Drug: Dehydroepiandrosterone [DHEA]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03573323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02855268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Study: NCT00673582
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/day rosuvastatin
Study: NCT00673582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 10 mg a day for 96 weeks
Study: NCT02602522
Drug: Shandong Danshen-Jiang-Fu Granule
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
Study: NCT02602522
Drug: Sichuan Danshen-Jiang-Fu Granule
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
Study: NCT00261053
Drug: i.v. recombinant human C1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04364269
Drug: VIT-2763 once a day (QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Study: NCT04364269
Drug: VIT-2763 twice a day (BID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.